INT38674

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1986
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 32
Total Number 33
Disease Relevance 19.00
Pain Relevance 2.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (KRT20) cytoplasm (KRT20)
Anatomy Link Frequency
B cells 5
T cells 2
leucocyte 1
stem cells 1
KRT20 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 51 99.00 Very High Very High Very High
anakinra 1 98.08 Very High Very High Very High
rheumatoid arthritis 140 97.28 Very High Very High Very High
withdrawal 3 97.00 Very High Very High Very High
imagery 28 94.48 High High
Angina 1 94.28 High High
abatacept 17 93.44 High High
Pain 8 91.84 High High
methotrexate 27 90.08 High High
Multiple sclerosis 140 86.32 High High
Disease Link Frequency Relevance Heat
Hodgkin's Disease 96 100.00 Very High Very High Very High
Thrombosis 2 99.92 Very High Very High Very High
Lymphatic System Cancer 326 99.84 Very High Very High Very High
Epstein-barr Virus 62 98.88 Very High Very High Very High
Brain Tumor 3 98.28 Very High Very High Very High
Malignant Neoplastic Disease 48 97.68 Very High Very High Very High
Endometrial Cancer 153 97.64 Very High Very High Very High
Autoimmune Disease 21 97.40 Very High Very High Very High
Rheumatoid Arthritis 145 97.28 Very High Very High Very High
Infection 88 96.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Rituximab targets the CD20 molecule, which is selectively expressed on B cells and depletes these cells [26].
Regulation (targets) of CD20 in B cells
1) Confidence 0.44 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833979 Disease Relevance 1.03 Pain Relevance 0.38
It is generally accepted that the CD20 protein functions as a channel regulator of ion influx (Ernst et al 2005) and that this membrane-bound protein is specifically found on the membrane of B-cells but is not expressed on stem cells nor on terminally-differentiated plasma cells.
Neg (nor) Regulation (regulator) of CD20 in stem cells
2) Confidence 0.37 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721296 Disease Relevance 0.78 Pain Relevance 0.23
Protein C values measured by the coagulant assay were compared to those obtained with amidolytic and immunochemical assays.
Regulation (values) of Protein
3) Confidence 0.23 Published 1986 Journal Thromb. Res. Section Abstract Doc Link 3798419 Disease Relevance 0.47 Pain Relevance 0.09
CD20 is not internalized or shed and appears to be an ideal target for immunotherapy.
Regulation (target) of CD20
4) Confidence 0.18 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012428 Disease Relevance 0.58 Pain Relevance 0
Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases.
Regulation (targeting) of CD20 in T cells associated with lymphatic system cancer and disease
5) Confidence 0.16 Published 2009 Journal Bone Marrow Transplant. Section Abstract Doc Link 18850012 Disease Relevance 0.87 Pain Relevance 0.05
Expanded use of rituximab in the management of non-Hodgkin lymphoma

Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20.

Regulation (targeting) of CD20 in B cell associated with hodgkin's disease
6) Confidence 0.10 Published 2009 Journal OncoTargets and therapy Section Title Doc Link PMC2886316 Disease Relevance 1.02 Pain Relevance 0
Some of these have been designed, like rituximab, to target the CD20 surface antigen.
Regulation (target) of CD20
7) Confidence 0.09 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004569 Disease Relevance 0.38 Pain Relevance 0
The chimeric monoclonal antibody rituximab, which targets the CD20 antigen on B lymphocytes, has been used extensively in the treatment of B cell malignancies.
Regulation (targets) of CD20 in B lymphocytes
8) Confidence 0.08 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC2833440 Disease Relevance 0.75 Pain Relevance 0.14
Rituximab is a chimeric monocolonal antibody targeting CD20+ B lymphocytes, which has been used for B-cell lymphomas as adjuvant chemotherapy.
Regulation (targeting) of CD20 in B-cell associated with lymphatic system cancer
9) Confidence 0.06 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2998807 Disease Relevance 0.72 Pain Relevance 0.18
The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B cell surface antigen CD20.
Regulation (targeting) of CD20 in B cells
10) Confidence 0.06 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526638 Disease Relevance 1.28 Pain Relevance 0.03
Some of these have been designed to target the CD20 antigen, like rituximab.
Regulation (target) of CD20
11) Confidence 0.06 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004569 Disease Relevance 0.41 Pain Relevance 0
Thus, the CD20 antigen has been an appealing target for therapy.
Regulation (target) of CD20
12) Confidence 0.06 Published 2010 Journal Cancer management and research Section Abstract Doc Link PMC3004569 Disease Relevance 0.66 Pain Relevance 0
Galectin-1 (Gal1) is an immunomodulatory glycan-binding protein regulated by an AP1-dependent enhancer in HRS cells and its expression affects the microenvironment in HL.
Regulation (regulated) of protein associated with hodgkin's disease
13) Confidence 0.05 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 1.10 Pain Relevance 0.03
In two Latin-American pediatric HL series, EBV-encoded RNAs in situ hybridization and latent membrane protein 1 immunohistochemistry on HL biopsies from 176 pediatric patients was positive in 52% of cases.
Regulation (positive) of protein associated with epstein-barr virus and hodgkin's disease
14) Confidence 0.05 Published 2008 Journal J Hematop Section Body Doc Link PMC2713479 Disease Relevance 2.27 Pain Relevance 0
However, biopsy revealed the cells to be immunopositive for CD20 and CD79a, and immunonegative for CD5, CD10, CD43, and CD23.
Regulation (immunopositive) of CD20
15) Confidence 0.05 Published 2010 Journal South. Med. J. Section Abstract Doc Link 20689487 Disease Relevance 0.85 Pain Relevance 0.14
Immunohistochemical staining was positive for leucocyte common antigen (LCA), CD10, CD20, CD79, and terminal deoxynucleotidyl transferase (TdT).
Regulation (positive) of CD20 in leucocyte
16) Confidence 0.05 Published 2009 Journal Int J Oral Maxillofac Surg Section Abstract Doc Link 19665353 Disease Relevance 0.75 Pain Relevance 0.13
Further new monoclonal antibodies targeting CD20 have been developed which are fully humanized (ofatumumab and GA-101-R05072759), or >90% humanized (veltumumab).16 They have mainly been applied to patients with lymphoma or rheumatoid arthritis.
Regulation (targeting) of CD20 associated with lymphatic system cancer and rheumatoid arthritis
17) Confidence 0.05 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2943198 Disease Relevance 1.09 Pain Relevance 0.12
Future studies are needed to address numerous questions including but not limited to whether: 1) isoflavones independent of soy protein can prevent ovarian hormone deficiency-associated bone loss; 2) consumption of soy containing food or intake of isoflavones on a daily basis is necessary to observe the expected beneficial effects on bone or simply intermittent use will produce the same results; 3) the effect of soy protein or its isoflavones on bone is transitory; and 4) the combination of soy isoflavones and lower doses of antiresorptive agents can prevent postmenopausal bone mineral loss.
Regulation (effect) of soy protein
18) Confidence 0.04 Published 2005 Journal Nutr J Section Body Doc Link PMC554088 Disease Relevance 0.08 Pain Relevance 0
Apart from anti-TNFalpha, several other biological treatments are now available, including those that target CD20 on B cells (rituximab), cytokines such as IL1 (anakinra) and IL6 (tocilizumab), and molecules that cause interaction between antigen presenting cells and T cells (abatacept).
Regulation (target) of CD20 in T cells associated with anakinra, abatacept and cytokine
19) Confidence 0.03 Published 2010 Journal Postgrad Med J Section Abstract Doc Link 20354048 Disease Relevance 1.19 Pain Relevance 0.63
Results suggest that these multiple spots represent single proteins that have undergone differential posttranslational modifications that alter the protein’s intrinsic charge and/or relative molecular weight.
Regulation (alter) of protein
20) Confidence 0.02 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2565687 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox